Addition of a Genetic Risk Score for Identification of Men with a Low Prostate-specific Antigen Level in Midlife at Risk of Developing Lethal Prostate Cancer

Men with a low prostate-specific antigen (PSA) level (<1 ng/ml) in midlife may extend the rescreening interval (if aged 40–59 yr) or forgo future PSA screening (if aged >60 yr) owing to their low risk of aggressive prostate cancer (PCa). However, there is a subset of men who develop lethal PCa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Chaoran, Ericsson, Caroline, Carlsson, Sigrid V., Lilja, Hans, Kibel, Adam, Graff, Rebecca E., Plym, Anna, Giovannucci, Edward, Mucci, Lorelei A., Preston, Mark A., Penney, Kathryn L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Brief Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969275/
https://www.ncbi.nlm.nih.gov/pubmed/36861107
http://dx.doi.org/10.1016/j.euros.2023.01.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969275/
https://www.ncbi.nlm.nih.gov/pubmed/36861107
http://dx.doi.org/10.1016/j.euros.2023.01.012

Ejemplares similares